Insulin resistance is known to be associated with mood disorders and cognitive difficulties.
The purpose of this study is to treat depressed patients with rosiglitazone (also known as
[AKA] Avandia), therefore improving glucose sensitivity, which in turn has the potential to
affect mood and thinking. We, the researchers at Stanford University, are recruiting men and
women who have been diagnosed with depression, and are willing to participate in this 3 month
study. Participation involves neuropsychological testing, 2 blood draws called an oral
glucose tolerance test (OGTT), which tests for glucose and insulin levels, and the
medication, rosiglitazone. Participants are allowed to continue on their current psychiatric
medication.